Try our mobile app

Published: 2022-08-16 16:01:09 ET
<<<  go to SY company page
EX-99.1 2 tm2223577d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

So-Young Reports Unaudited Second Quarter 2022 Financial Results

 

BEIJING, China, Aug. 16, 2022 — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the second quarter ended June 30, 2022.

 

Second Quarter 2022 Financial Highlights

 

Total revenues were RMB309.1 million (US$46.1 million1), a decrease of 31.6% from RMB451.8 million in the same period of 2021.

 

Net loss attributable to So-Young International Inc. was RMB32.3 million (US$4.8 million), compared with net income attributable to So-Young International Inc. of RMB57.6 million in the second quarter of 2021.

 

Non-GAAP net loss attributable to So-Young International Inc.2 was RMB22.7 million (US$3.4 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB73.7 million in the same period of 2021.

 

Second Quarter 2022 Operational Highlights

 

Average mobile MAUs were 3.5 million, compared with 10.0 million in the second quarter of 2021.

 

Number of paying medical service providers on So-Young’s platform were 5,735, an increase of 17.1% from 4,899 in the second quarter of 2021.

 

Number of medical service providers subscribing to information services on So-Young’s platform were 2,622, compared with 2,236 in the second quarter of 2021.

 

Total number of purchasing users through reservation services were 129.5 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB353.1 million.

 

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “In this quarter, we recorded a solid result, which also demonstrated our resilience amid COVID-19 resurgence and soft consumer sentiment. Benefiting from our digital capabilities and innovative user experience, the number of paying medical service providers on So-Young’s platform increased by 17.1% year-over-year to 5,735.”

 

Mr. Jin continued, “In the current challenging environment, our business remained on track, and we are also refining our infrastructure capacity. Recently, we launched “So-Young Select” strategy to help medical service providers improve operating efficiency and support users in making better decisions. Looking ahead, we are committed to having a healthy growth strategy and create more value to reaffirm our leadership position.”

 

 

1 This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.6981 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on June 30, 2022.

 

2 Non-GAAP net loss attributable to So-Young International Inc. is defined as net loss attributable to So-Young International Inc. excluding share-based compensation expenses. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.

 

1 

 

 

Mr. Min Yu, Chief Financial Officer of So-Young, commented, “We are encouraged to see a gradual recovery and a steady increase quarter-over-quarter on the top line. Meanwhile, we were prudent with our expenses management and narrowed our loss in the quarter. As a result, the non-GAAP net loss attributable to So-Young International Inc. narrowed by more than 53.0% quarter-over-quarter. Going forward, we will continue to execute our business strategies and keep a healthy cash reserve with RMB1,598.9 million as of June 30, 2022 to generate long-term shareholder value.”

 

Second Quarter 2022 Financial Results

 

Revenues

 

Total revenues were RMB309.1 million (US$46.1 million), a decrease of 31.6% from RMB451.8 million in the same period of 2021. The decrease was primarily due to a decrease in average revenue per paying medical service provider which was impacted by the resurgence of COVID-19 and the weakening macro-economic environment.

 

Information services and other revenues were RMB219.3 million (US$32.7 million), a decrease of 39.2% from RMB360.7 million in the same period of 2021. The decrease was primarily due to a decrease in average revenue per paying medical service provider subscribing to information services.

 

Reservation services revenues were RMB30.6 million (US$4.6 million), a decrease of 66.4% from RMB91.1 million in the same period of 2021.The decrease was primarily due to the impact by the resurgence of COVID-19 in certain cities in China and adoption of new operating strategy which gave higher subsidies to end users.

 

Sales of equipment and maintenance services revenues were RMB59.1 million (US$8.8 million), from Wuhan Miracle Laser Systems, Inc. (“Wuhan Miracle”).

 

Cost of Revenues

 

Cost of revenues were RMB104.5 million (US$15.6 million), an increase of 77.7% from RMB58.8 million in the second quarter of 2021. The increase was primarily due to the consolidation of Wuhan Miracle. Cost of revenues included share-based compensation expenses of RMB2.7 million (US$0.4 million) during the second quarter of 2022, compared with RMB3.8 million in the corresponding period of 2021.

 

Operating Expenses

 

Total operating expenses were RMB246.6 million (US$36.8 million), a decrease of 26.5% from RMB335.4 million in the second quarter of 2021.

 

Sales and marketing expenses were RMB121.7 million (US$18.2 million), a decrease of 41.1% from RMB206.7 million in the second quarter of 2021. The decrease was primarily due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses for the second quarter of 2022 included share-based compensation expenses of RMB2.2 million (US$0.3 million), compared with RMB1.6 million in the corresponding period of 2021.

 

General and administrative expenses were RMB61.8 million (US$9.2 million), an increase of 9.4% from RMB56.5 million in the second quarter of 2021. The increase was primarily due to the consolidation of Wuhan Miracle and the increase of professional services fee. General and administrative expenses for the second quarter of 2022 included share-based compensation expenses of RMB2.2 million (US$0.3 million), compared with RMB7.2 million in the corresponding period of 2021.

 

Research and development expenses were RMB63.1 million (US$9.4 million), a decrease of 12.5% from RMB72.1 million in the second quarter of 2021. The decrease was primarily attributable to a decrease in payroll costs associated with the employee headcount. Research and development expenses for the second quarter of 2022 included share-based compensation expenses of RMB2.5 million (US$0.4 million), compared with RMB3.6 million in the corresponding period of 2021.

 

2 

 

 

Income tax (expenses)/benefit

 

Income tax benefit was RMB0.1 million (US$0.0 million), compared with income tax expenses of RMB11.1 million in the same period of 2021.

 

Net income/(loss) attributable to So-Young International Inc.

 

Net loss attributable to So-Young International Inc. was RMB32.3 million (US$4.8 million), compared with a net income attributable to So-Young International Inc. of RMB57.6 million in the second quarter of 2021.

 

Non-GAAP Net income/(loss) attributable to So-Young International Inc.

 

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, was RMB22.7 million (US$3.4 million), compared with RMB73.7 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2021.

 

Basic and Diluted Earnings/(loss) per ADS

 

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.30 (US$0.04) and RMB0.30 (US$0.04), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.54 and RMB0.53, respectively, in the same period of 2021.

 

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

 

As of June 30, 2022, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,598.9 million (US$238.7 million), compared with RMB1,756.0 million as of December 31, 2021.

 

Business Outlook

 

For the third quarter of 2022, So-Young expects total revenues to be between RMB310 million (US$46.3 million) and RMB330 million (US$49.3 million), representing a 28.1% to 23.5% decrease from the same period in 2021. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, as well as customer demand, which are all subjected to change, particularly in view of the potential impact of the COVID-19, the effects of which are difficult to analyze and predict.

 

Non-GAAP Financial Measures

 

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP (loss)/income from operations and non-GAAP net (loss)/income attributable to So-Young International Inc. by excluding share-based compensation expenses from (loss)/income from operations and net (loss)/income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. This is not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

 

Conference Call Information

 

So-Young’s management will hold an earnings conference call on Tuesday, August 16, 2022, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Participants can register for the conference call by navigating to https://s1.c-conf.com/DiamondPass/10024340-hd864t.html.

 

3 

 

 

Once preregistration has been completed, participants will receive dial-in numbers, an event passcode, and a unique registrant ID.

 

To join the conference, please dial the number you receive, enter the event passcode followed by your unique registrant ID, and you will be joined to the conference instantly.

 

A telephone replay will be available two hours after the conclusion of the conference call until midnight U.S. Eastern Time, August 23, 2022. The dial-in details are:

 

International: +61 7 3107 6325
US: +1855 883 1031
Passcode: 10024340

 

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

 

About So-Young International Inc.

 

So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to fourth parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; the impact of the COVID-19 pandemic to So-Young’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

 

4 

 

 

For more information, please contact:

 

So-Young

 

Investor Relations

Ms. Vivian Xu

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

 

Christensen

 

In China

Mr. Eric Yuan

Phone: +86-10-5900-1548

E-mail: Eyuan@christensenir.com

 

In US

Ms. Linda Bergkamp

Phone: +1-480-614-3004

Email: lbergkamp@christensenir.com

 

5 

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)

 
   As of 
   December 31,   June 30,   June 30, 
   2021   2022   2022 
   RMB   RMB   US$ 
Assets               
Current assets:               
Cash and cash equivalents   1,331,968    1,471,756    219,727 
Restricted cash and term deposits   15,119    16,504    2,464 
Trade receivables   54,829    40,686    6,074 
Inventories, net   91,812    94,614    14,125 
Receivables from online payment platforms   18,864    15,760    2,353 
Amounts due from related parties   14,038    28,502    4,255 
Term deposits and short-term investments   408,946    110,592    16,511 
Prepayment and other current assets   91,842    127,079    18,972 
Total current assets   2,027,418    1,905,493    284,481 
Non-current assets:               
Long-term investments   252,500    250,988    37,472 
Intangible assets   193,955    181,881    27,154 
Goodwill   540,693    540,693    80,723 
Property and equipment, net   124,576    120,433    17,980 
Deferred tax assets   47,520    47,882    7,149 
Operating lease right-of-use assets   95,609    82,667    12,342 
Other non-current assets   48,097    105,828    15,800 
Total non-current assets   1,302,950    1,330,372    198,620 
Total assets   3,330,368    3,235,865    483,101 
                
Liabilities               
Current liabilities:               
Taxes payable   48,571    51,866    7,743 
Contract liabilities   139,155    127,415    19,023 
Salary and welfare payables   103,624    75,268    11,237 
Amounts due to related parties   681    47    7 
Accrued expenses and other current liabilities   376,841    354,381    52,906 
Operating lease liabilities-current   43,529    52,341    7,814 
Total current liabilities   712,401    661,318    98,730 
Non-current liabilities:               
Operating lease liabilities-non current   62,356    42,735    6,380 
Deferred tax liabilities   38,577    35,478    5,297 
Total non-current liabilities   100,933    78,213    11,677 
Total liabilities   813,334    739,531    110,407 
                
Shareholders’ equity:               
Treasury stock   (217,712)   (217,712)   (32,504)
Class A Ordinary shares (US$ 0.0005 par value;  750,000,000 shares authorized as of December 31, 2021 and June 30, 2022;  71,736,059 and 69,092,367 shares issued and outstanding as of December 31, 2021, 72,060,295 and 69,416,603 shares issued and outstanding as of June 30, 2022, respectively)   230    232    34 
Class B Ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2021 and June 30, 2022; 12,000,000 shares issued and outstanding as of December 31, 2021 and June 30, 2022)   37    37    6 
Additional paid-in capital   2,999,562    3,028,134    452,089 
Statutory reserves   20,331    20,331    3,035 
Accumulated deficit   (272,368)   (371,505)   (55,464)
Accumulated other comprehensive loss   (83,891)   (33,505)   (5,002)
Total So-Young International Inc. shareholders’ equity   2,446,189    2,426,012    362,194 
                
Non-controlling interests   70,845    70,322    10,500 
                
Total shareholders’ equity   2,517,034    2,496,334    372,694 
Total liabilities and shareholders’ equity   3,330,368    3,235,865    483,101 

 

6 

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Six Months Ended 
   June 30, 2021   June 30, 2022   June 30, 2022   June 30, 2021   June 30, 2022   June 30, 2022 
   RMB   RMB   US$   RMB   RMB   US$ 
Revenues                        
Information services and others   360,714    219,343    32,747    638,547    418,874    62,536 
Reservation services   91,131    30,616    4,571    172,943    72,969    10,894 
Sales of equipment and maintenance services   -    59,120    8,827    -    117,582    17,555 
Total revenues   451,845    309,079    46,145    811,490    609,425    90,985 
Cost of revenues   (58,807)   (104,479)   (15,598)   (111,161)   (211,062)   (31,511)
Gross profit   393,038    204,600    30,547    700,329    398,363    59,474 
Operating expenses:                              
Sales and marketing expenses   (206,730)   (121,740)   (18,175)   (449,088)   (248,953)   (37,169)
General and administrative expenses   (56,494)   (61,794)   (9,226)   (111,671)   (127,186)   (18,988)
Research and development expenses   (72,132)   (63,089)   (9,419)   (141,935)   (142,023)   (21,203)
Total operating expenses   (335,356)   (246,623)   (36,820)   (702,694)   (518,162)   (77,360)
Income/(loss) from operations   57,682    (42,023)   (6,273)   (2,365)   (119,799)   (17,886)
Other income/(expenses):                              
Investment income   3,064    1,068    159    5,732    3,504    523 
Interest income   4,771    5,347    798    10,771    8,546    1,276 
Exchange gains/(losses)   358    (600)   (90)   (4,353)   (539)   (80)
Share of income/(losses) of equity method investee   54    (833)   (124)   133    (1,902)   (284)
Others, net   1,499    4,425    661    6,904    8,381    1,251 
Income/(Loss) before tax   67,428    (32,616)   (4,869)   16,822    (101,809)   (15,200)
Income tax (expenses)/benefit   (11,122)   55    8    (6,788)   2,056    307 
Net income/(loss)   56,306    (32,561)   (4,861)   10,034    (99,753)   (14,893)
Net loss attributable to noncontrolling interests   1,288    265    40    2,563    616    92 
Net income/(loss) attributable to So-Young International Inc.   57,594    (32,296)   (4,821)   12,597    (99,137)   (14,801)
                               
Net income/(loss) per ordinary share                              
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - basic   0.70    (0.39)   (0.06)   0.15    (1.20)   (0.18)
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - diluted   0.69    (0.39)   (0.06)   0.15    (1.20)   (0.18)
Net earnings/(loss) per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares)   0.54    (0.30)   (0.04)   0.12    (0.92)   (0.14)
Net earnings/(loss) per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares)   0.53    (0.30)   (0.04)   0.12    (0.92)   (0.14)
Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic*   82,403,282    82,709,017    82,709,017    82,260,972    82,394,496    82,394,496 
Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted*   83,023,318    82,709,017    82,709,017    83,695,653    82,394,496    82,394,496 
                               
Share-based compensation expenses included in:                              
Cost of revenues   (3,791)   (2,662)   (397)   (8,124)   (5,296)   (791)
Sales and marketing expenses   (1,550)   (2,236)   (334)   (3,844)   (5,672)   (847)
General and administrative expenses   (7,246)   (2,249)   (336)   (14,414)   (10,163)   (1,517)
Research and development expenses   (3,564)   (2,478)   (370)   (8,680)   (7,070)   (1,056)

 

*Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

7 

 

 

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)

 

   For the Three Months Ended   For the Six Months Ended 
   June 30, 2021   June 30, 2022   June 30, 2022   June 30, 2021   June 30, 2022   June 30, 2022 
   RMB   RMB   US$   RMB   RMB   US$ 
GAAP Income/(loss) from operations   57,682    (42,023)   (6,273)   (2,365)   (119,799)   (17,886)
Add back: Share-based compensation expenses   16,151    9,625    1,437    35,062    28,201    4,211 
Non-GAAP Income/(loss) from operations   73,833    (32,398)   (4,836)   32,697    (91,598)   (13,675)
                               
GAAP Net income/(loss) attributable to So-Young International Inc.   57,594    (32,296)   (4,821)   12,597    (99,137)   (14,801)
Add back: Share-based compensation expenses   16,151    9,625    1,437    35,062    28,201    4,211 
Non-GAAP Net income/(loss) attributable to So-Young International Inc.   73,745    (22,671)   (3,384)   47,659    (70,936)   (10,590)

 

8